NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

CompletedN/A

Sponsor: AstraZeneca

Conditions: Hypereosinophilic Syndrome (HES)

Interventions: no intervention, no intervention

Countries: United States

The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis record of HES (ICD-10-CM D72.11) anytime during 01 October 2020 to 30 June 2023
* At least 12 months of patient insurance record prior to first HES record.

Exclusion Criteria:

* Any mutation in PDGFRA, PDGFRB or FGFR1 genes (to exclude clonal HES).
* History of BCR-ABL tyrosine kinase inhibitor use: imatinib, dasatinib, nolitinib, bosutinib, ponatinib, asciminib (to exclude clonal HES)
* History of myeloid leukemia, myeloproliferative disorder, myelodysplastic disorder, myelomonocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukaemia, acute panmyelosis with myelofibrosis, and other specified leukaemias (to exclude reactive HES)
* History of helminthiasis or use of anthelmintic medication (to exclude reactive HES)
* History of autoimmune disease (to exclude reactive HES)
* History of use of specific drugs: antiepileptics, sulfonamides, allopurinol, and immune checkpoint inhibitors (to exclude reactive HES)

Locations (1)

Cambridge, Massachusetts, United States